Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States

[1] Woolf SH(2021)COVID-19 as the leading cause of death in the United States JAMA 325 123-124

[2] Chapman DA(2010)Diabetes and cancer: a consensus report CA: Cancer J Clin 60 207-221

[3] Lee JH(2000)Cancer and comorbidity: redefining chronic diseases Cancer 88 653-663

[4] Giovannucci E(2011)Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion Science 331 1565-1570

[5] Harlan DM(2021)COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries Rheumatology 34 1211-1213

[6] Archer MC(2011)Additional autoimmune disease found in 33% of patients at type 1 diabetes onset Diabetes Care 7 220-227

[7] Ogle KS(2021)Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection JAMA Oncol 79 1156-1162

[8] Swanson GM(2020)Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Ann Rheum Dis 3 111-115

[9] Woods N(2021)Autoimmune and chronic inflammatory disease patients with COVID-19 ACR Open Rheumatol 48 454-462

[10] Azzouz F(2021)Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City J Rheumatol 395 1907-1918

[1] Woolf SH(2021)COVID-19 as the leading cause of death in the United States JAMA 325 123-124

[2] Chapman DA(2010)Diabetes and cancer: a consensus report CA: Cancer J Clin 60 207-221

[3] Lee JH(2000)Cancer and comorbidity: redefining chronic diseases Cancer 88 653-663

[4] Giovannucci E(2011)Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion Science 331 1565-1570

[5] Harlan DM(2021)COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries Rheumatology 34 1211-1213

[6] Archer MC(2011)Additional autoimmune disease found in 33% of patients at type 1 diabetes onset Diabetes Care 7 220-227

[7] Ogle KS(2021)Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection JAMA Oncol 79 1156-1162

[8] Swanson GM(2020)Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Ann Rheum Dis 3 111-115

[9] Woods N(2021)Autoimmune and chronic inflammatory disease patients with COVID-19 ACR Open Rheumatol 48 454-462

[10] Azzouz F(2021)Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City J Rheumatol 395 1907-1918